Citius Pharma Files 10-K/A Amendment

Ticker: CTXR · Form: 10-K/A · Filed: Jan 27, 2025 · CIK: 1506251

Sentiment: neutral

Topics: amendment, annual-report, pharmaceuticals

TL;DR

Citius Pharma filed their 2024 10-K/A, check for updates.

AI Summary

Citius Pharmaceuticals, Inc. filed an amendment (10-K/A) on January 27, 2025, for their fiscal year ending September 30, 2024. The company, previously known as Trail One, Inc., is incorporated in Nevada and operates in the pharmaceutical preparations industry. Their principal executive offices are located in Cranford, NJ.

Why It Matters

This filing provides updated information for the fiscal year 2024, which is crucial for investors to assess the company's financial health and operational status.

Risk Assessment

Risk Level: low — This is a routine amendment to a previously filed annual report, not indicating new significant risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 10-K/A filing?

This is Amendment No. 1 to the Form 10-K for the fiscal year ended September 30, 2024, indicating updates or corrections to the original filing.

What was Citius Pharmaceuticals, Inc. formerly known as?

Citius Pharmaceuticals, Inc. was formerly known as Trail One, Inc., with name changes noted in 2011 and 2010.

In which state is Citius Pharmaceuticals, Inc. incorporated?

The company is incorporated in Nevada.

What is the principal business address of Citius Pharmaceuticals, Inc.?

The principal executive offices are located at 11 Commerce Drive, First Floor, Cranford, NJ 07016.

What is the SIC code for Citius Pharmaceuticals, Inc.?

The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 2,698 words · 11 min read · ~9 pages · Grade level 8.1 · Accepted 2025-01-27 16:13:14

Key Financial Figures

Filing Documents

Signatures

Signatures 5 i PART IV Item 15. Exhibits and Financial Statement Schedules Exhibit Number Description of Document Registrant's Form Dated Exhibit Number Filed Herewith 2.1+ Agreement and Plan of Merger, dated as of October 23, 2023, by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition, and TenX Merger Sub Inc. 8-K 10/24/2023 2.1 3.1 Amended and Restated Articles of Incorporation of Citius Pharmaceuticals, Inc. 8-K 9/18/2014 3.1 3.2 Certificate of Amendment to the Amended and Restated Articles of Incorporation of Citius Pharmaceuticals, Inc., effective September 16, 2016. 8-K 9/21/2016 3.1 3.3 Certificate of Amendment to the Amended and Restated Articles of Incorporation of Citius Pharmaceuticals, Inc., effective June 9, 2017. 8-K 6/8/2017 3.1 3.4 Certificate of Amendment to the Articles of Incorporation of Citius Pharmaceuticals Inc., dated June 21, 2021. 8-K/A 6/22/2021 3.1 3.5 Amended and Restated Bylaws of Citius Pharmaceuticals, Inc. 8-K 2/9/2018 3.1 3.6 Certificate of Change filed with the Secretary of State of Nevada on November 22, 2024. 8-K 11/26/2024 3.1 4.1 Form of Common Stock Purchase Warrant, dated August 13, 2018, as amended August 8, 2023. 10-K 12/29/2023 4.1 4.2 Form of Pre-Funded Common Stock Purchase Warrant, dated August 13, 2018. 8-K 8/13/2018 4.2 4.3 Form of Underwriter's Common Stock Purchase Warrant, dated August 13, 2018, as amended August 8, 2023. 10-K 12/29/2023 4.3 4.4 Form of Investor Warrant issued April 3, 2019. 8-K 4/03/2019 4.1 4.5 Form of Placement Agent Warrant issued April 3, 2019. 8-K 4/03/2019 4.2 4.6 Form of Common Stock Purchase Warrant issued September 27, 2019. 8-K 9/27/2019 4.1 4.7 Form of Underwriters Common Stock Purchase Warrant issued September 27, 2019. 8-K 9/27/2019 4.3 4.8 Form of Investor Warrant issued on February 19

Description of Common Stock

Description of Common Stock. 10-K 12/27/24 4.22 10.1* Citius Pharmaceuticals, Inc. 2014 Stock Incentive Plan. 10-Q 8/15/2016 10.1 10.2* Form of Citius Pharmaceuticals, Inc. 2014 Stock Incentive Plan Nonqualified Stock Option. 10-Q 8/15/2016 10.2 10.3* Amended and Restated Employment Agreement between Myron Holubiak and Citius Pharmaceuticals, Inc., executed April 12, 2022, effective May 1, 2022 . 10-Q 5/12/2022 10.1 10.4 Second Amendment to the Patent and Technology License Agreement between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc., dated March 20, 2017 . 10-Q 5/15/2017 10.8 10.5* Amended and Restated Employment Agreement between Leonard Mazur and Citius Pharmaceuticals, Inc., dated October 19, 2017. 10-K 12/11/2018 10.23 10.6* Employment Agreement between Jaime Bartushak and Citius Pharmaceuticals, Inc., dated November 27, 2017. 8-K 12/1/2017 10.1 10.7* Citius Pharmaceuticals, Inc. 2018 Omnibus Stock Incentive Plan 10-Q 2/14/2018 10.2 10.8 Form of Securities Purchase Agreement between Citius Pharmaceuticals, Inc. and the purchasers named therein, dated March 28, 2018. 8-K 3/29/2018 10.1 10.9+ Patent and Technology License Agreement, dated January 2, 2019, between the Board of Regents of the University of Texas System on behalf of the University of Texas M. D. Anderson Cancer Center and Citius Pharmaceuticals, Inc. 10-Q 2/14/2019 10.1 10.10 First Amendment, dated October 15, 2015, to Patent and Technology License Agreement, dated May 14, 2014, between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc. 10-Q 2/14/2019 10.2 10.11+ Patent and Technology License Agreement, dated May 14, 2014, between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc. 10-Q 5/12/2023 10.1 2 Exhibit Number Description of Document Registrant's Form Dated Exhibit Number Filed Herew

SIGNATURES

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: January 27, 2025 By: /s/ Leonard Mazur Leonard Mazur Chief Executive Officer (Principal Executive Officer) 5

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on Read The Filing